Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Adoptive T-cell therapy for cancer: The era of engineered T cellsRe-adapting T cells for cancer therapy: from mouse models to clinical trials.MicroRNA-150 modulates intracellular Ca 2+ levels in naïve CD8+ T cells by targeting TMEM20.E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma modelMolecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity.Serine Phosphorylation of SLP76 Is Dispensable for T Cell Development but Modulates Helper T Cell Function.Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeAbrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivoNew Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesThe role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation.Enhancing adoptive T cell immunotherapy with microRNA therapeutics.Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene TherapyEnhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytesAnnular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse.A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells.Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.T-cell tolerance in cancer.Cbl-family proteins as regulators of cytoskeleton-dependent phenomena.CD28z CARs and armored CARsThe rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelReinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.Immune Regulation by Ubiquitin Tagging as Checkpoint Code.Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.
P2860
Q21131200-881281E4-69F3-4907-AFC3-A7E425385ECEQ26744624-6943245D-1749-447C-B651-27090A2E13C9Q26800611-4B4ABD9C-475A-43C5-8569-7763815707C6Q33588711-52584567-2A6C-44E0-9D24-805B809303C2Q33752767-B87EE8BD-3524-427F-942E-BB058E457B1CQ33953086-A21BD856-6466-48E1-A015-08BB1640CCFAQ34409836-6EE9C9B5-34A7-4EA4-8C9E-FC23B247E41EQ35463260-94BF62B9-1508-43B1-BB01-0F8D3E50421EQ35735738-A7BDB1DD-BC77-450C-8519-E51AC20D0894Q36255620-1E64FB00-EA0B-4BBB-B299-81BE4147CB41Q36340873-E731E0D5-776B-4866-BD3F-7D43A576BDD4Q36466018-39BBAF3A-CCBF-4F6F-B04C-929E4B9A833EQ36558375-69F319FE-CFAE-4384-A3BE-254B515DBF38Q36754726-D24CCBE5-B95C-42F3-AC71-DD263BD56F58Q36889204-BD717960-3567-4C6F-B366-4759167D0371Q36928580-4835D091-57DD-4FA7-8925-4589F90FB2E1Q36941051-B85DA4FB-941A-4DF9-835C-92F44DC02E7FQ37113080-B2C4FD7D-9F36-4914-A407-F1958BDC7FC6Q37322193-84847FBF-EF98-4174-A14B-8DE4E4E80472Q37588247-938C0C78-16A1-44D6-B14B-C544D5CB498BQ37607147-2CB1AE61-2F9E-4E61-A1F0-787E53B87039Q38103582-DC64314D-552C-4E58-9446-A5A2974A7F52Q38112644-CB72D8EE-9676-4582-BD78-B7D692993C62Q38199347-CE7D5D71-47BF-48B6-9B37-3D157D1964B3Q38206518-3380D705-4561-4F83-B400-4B616E2557CEQ39249589-D9D67039-0A3D-43CA-A2C2-4FA78F8FDFA4Q39579695-C5694E2D-F82B-4297-AE03-04A3B210EAA2Q40895579-003E8AD2-64F7-41E0-9607-A1C605344453Q47637581-C19CA5DE-B13F-4271-A260-4665759CBEAFQ47774246-C8AC02F2-3CD0-43D1-A775-F8D62F9FB70AQ55362771-28D9DB86-C908-4F86-B05C-0CE156D1F4F3
P2860
Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Abrogating Cbl-b in effector CD8
@nl
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@ast
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@en
type
label
Abrogating Cbl-b in effector CD8
@nl
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@ast
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@en
prefLabel
Abrogating Cbl-b in effector CD8
@nl
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@ast
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@en
P2093
P2860
P356
P1476
Abrogating Cbl-b in effector C ...... e therapy of leukemia in mice.
@en
P2093
Ingunn M Stromnes
Joseph N Blattman
Philip D Greenberg
Sara Jeevanjee
Xiaoxia Tan
P2860
P304
P356
10.1172/JCI41991
P407
P577
2010-09-20T00:00:00Z